Sam Williams

Sam is Managing Partner, Life Sciences, at IPGroup.

Sam has over 20 years’ experience in the biotechnology industry, both as a top-ranked equity analyst in the City and, subsequently, as an investor and chief executive. He is Founder and Executive Chairman of Istesso Limited, a Phase 2 drug-discovery company, and oversees the Life Sciences portfolio for the FTSE250 company IP Group plc. He serves as a non-executive director of Diurnal Group plc, Microbiotica Ltd, Psioxus Ltd and Kuur Therapeutics Ltd. Sam holds a PhD in molecular biology from Cambridge and a degree in biology from Oxford.